Summary of preliminary treat-to-target recommendations.
| 1 | A state of clear or almost clear skin should be a therapeutic target for psoriasis regardless of the area affected (e.g., nails, scalp, soles, palms, trunk, extremities, etc.) and the duration of disease (early vs late disease). |
| 2 | Because a state of remission may be difficult to reach in psoriatic arthritis, a state of minimal disease activity is an acceptable therapeutic target. |
| 3 | Quality of life is an important outcome from the patient and physician perspective and should be included in therapeutic targets. |
| 4 | Functional impairment, comorbidities, and treatment risks should be considered when making clinical decisions in addition to assessing measures of disease activity. |
| 5 | Physicians and patients must be in agreement regarding selected therapeutic targets, taking into consideration initial severity of disease and the appropriate time frame to reach this target. |
| 6 | Patients must be treated adequately to reach the selected therapeutic targets, with therapy adjustments every 3 months for patients with active disease and every 6 to 12 months for those with stable disease (when therapeutic targets are reached). |
| 7 | Once reached, the state of clear or almost clear skin should be maintained for as long as possible with adjustment in therapy at the first signs of disease progression. |
| 8 | Standard safety assessments should be performed at each visit. |